We provide the latest news
from the world of economics and finance
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At Ginkgo Bioworks Holdings, a filing with the SEC revealed that on Wednesday, Director Shyam Sankar bought 625,000 shares of DNA, at a cost of $0.82 each, for a total investment of $514,750. Ginkgo Bioworks Holdings is trading down about 3.2% on the day Friday. Before this latest buy, Sankar made one other buy in the past twelve months, purchasing $512,000 shares at a cost of $1.28 a piece.
And at Verve Therapeutics, there was insider buying on Tuesday, by Andrew D. Ashe who purchased 76,000 shares for a cost of $6.26 each, for a trade totaling $475,760. This buy marks the first one filed by Ashe in the past year. Verve Therapeutics is trading down about 3.1% on the day Friday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.